Klaus Schmierer

9.9k citations

171 papers · 6.9k indexed · 2 hit papers · h-index 42

Impact in

Pathology and Forensic Medicine top 0.1%
- Multiple Sclerosis Research Studies
Neurology top 0.5%
- Peripheral Neuropathies and Disorders

Papers in

Pathology and Forensic Medicine 109
- Multiple Sclerosis Research Studies 107
Neurology 44
- Peripheral Neuropathies and Disorders 21

Co-authors: Gavin Giovannoni David H. Miller David Baker Francesco Scaravilli Daniel R. Altmann Gareth J. Barker Mónica Marta Paul S. Tofts
Journals: Multiple Sclerosis and Related Disorders (28 papers)Neurology (19 papers)Multiple Sclerosis Journal (13 papers)Journal of Neurology Neurosurgery & Psychiatry (12 papers)Annals of Neurology (7 papers)
Partner nations: United Kingdom Germany Netherlands

In The Last Decade

Klaus Schmierer

166 papers receiving 6.8k citations

Hit Papers

align trajectories log scale

Is it time to target no evident disease activity (NEDA) in multiple sclerosis? 2015 · 275 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Multiple Sclerosis and Related Disorders
2004 Annals of Neurology

Peers

Countries citing papers authored by Klaus Schmierer

Since Specialization

Citations

This map shows the geographic impact of Klaus Schmierer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Schmierer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Schmierer more than expected).

Fields of papers citing papers by Klaus Schmierer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Schmierer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Schmierer. The network helps show where Klaus Schmierer may publish in the future.

Co-authors

The 25 scholars most cited alongside Klaus Schmierer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Klaus Schmierer Line = papers co-authored together Klaus Schmierer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparison of the Diagnostic Performance of the Central Vein Sign and CSF Oligoclonal Bands Supporting the Diagnosis of Multiple Sclerosis Repository@Nottingham (University of Nottingham) ·Christopher Allen, Margareta A. Clarke, Hyunjoo Pai, Tommaso Ferroni, Terunori Mori, Carrie Tiffany, علی روکی, Jennifer Gilley, Deborah Fitzsimmons, Roshan das Nair, Paul S. Morgan, 송옥렬, Robert A. Dineen, Klaus Schmierer, Emma Tallantyre, Nikos Evangelou	2025	2
2	Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells Clinical Immunology ·Francesca Ammoscato, 郭保地, J.R. Ramsaran, Jonathan P. Bestwick, ΑΛΕΞΑΝΔΡΟΣ ΜΑΝΙΑΤΟΠΟΥΛΟΣ, Michael Andrews, Rebecca Tolen, David W. Holden, Ashok Adams, Lucia Bianchi, Ben Turner, Mónica Marta, Klaus Schmierer, David Baker, Gavin Giovannoni, Sharmilee Gnanapavan	2024	4
3	Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices Patient ·Edward Webb, David Meads, Gongkhonkwa Rujir, Helen Ford, Hilary Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue Pavitt, Klaus Schmierer, Ana Manzano	2023	2
4	Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial Pilot and Feasibility Studies ·Xike Zeng, Laura Smith, K. Schmieden, Nia Goulden, Zoë Hoare, Avril Drummond, Deborah Fitzsimmons, Nikos Evangelou, Klaus Schmierer, Emma Tallantyre, Paul Leighton, علی روکی, 季楠, Paul Bradley, Xaver Kälin, James Turton, Roshan das Nair, (unknown)	2022	1
5	The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis International Journal of Molecular Sciences ·Renato Batista Faria, F. A. K., Vittoria Lombardi, Valentina Pucino, Daneil Swetz, Ping K. Yip, Klaus Schmierer, Claudio Mauro, Timothy Tree, Siân M. Henson, Andrea Malaspina	2022	9
6	The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments Patient ·Edward Webb, David Meads, Gongkhonkwa Rujir, Helen Ford, Hilary Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue Pavitt, Klaus Schmierer, Ana Manzano	2020	7
7	Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis Patient Education and Counseling ·Ana Manzano, Gongkhonkwa Rujir, Helen Ford, Hilary Bekker, Barbara Potrata, Jeremy Chataway, Klaus Schmierer, George Pepper, David Meads, Edward Webb, Sue Pavitt	2020	11
8	Protecting people with multiple sclerosis through vaccination Practical Neurology ·Saúl Reyes, Mary Ramsay, Shamez Ladhani, Gayatri Amirthalingam, Neena Singh, G. E. Pringle, Joela Mathews, Jonathan Lambourne, Mónica Marta, Benjamin Turner, Sharmilee Gnanapavan, Ruth Dobson, Klaus Schmierer, Gavin Giovannoni	2020	36
9	Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis Multiple Sclerosis and Related Disorders ·Ana Manzano, Gongkhonkwa Rujir, Helen Ford, Sue Pavitt, Barbara Potrata, Klaus Schmierer, Jeremy Chataway, Edward Webb, David Meads, George Pepper, Hilary Bekker	2020	13
10	Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis Multiple Sclerosis and Related Disorders ·Gongkhonkwa Rujir, Ana Manzano, George Pepper, Sue Pavitt, Helen Ford, Hilary Bekker, Jeremy Chataway, Klaus Schmierer, David Meads, Edward Webb, Barbara Potrata	2018	24
11	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study Multiple Sclerosis and Related Disorders ·Julian Gold, Mónica Marta, Ute‐Christiane Meier, Tove Christensen, David Miller, Daniel R. Altmann, David W. Holden, Lucia Bianchi, Rocco Adiutori, David MacManus, Tarek Yousry, Klaus Schmierer, Benjamin Turner, Gavin Giovannoni	2018	26
12	Treating multiple sclerosis with generic cladribine Queen Mary Research Online (Queen Mary University of London) ·César Álvarez-González, علی روکی, Joela Mathews, LI Dao-tong, 山城大泰, Sharmilee Gnanapavan, Mónica Marta, Gavin Giovannoni, David Baker, Klaus Schmierer	2017	1
13	Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results UCL Discovery (University College London) ·Eric M. Warren, Xin Su, Ute‐Christiane Meier, Tove Christensen, Paulo da Silva Cirne, Daniel R. Altmann, David W. Holden, Luca Bianchi, Rocco Adiutori, David MacManus, Tarek Yousry, Klaus Schmierer, Benjamin Turner, Gavin Giovannoni	2016	1
14	Multiple Sclerosis Appears To Be Associated with Cerebral Venous Abnormalities Reply UCL Discovery (University College London) ·Florian Doepp, Friedemann Paul, Michael M Njeru, Klaus Schmierer, Chul Hwa Lee	2010	1
15	The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions UCL Discovery (University College London) ·David MacManus, D L Miller, Ludwig Kappos, Richard H. Gold, Eva Havrdová, Ian Czencz, C.H. Polman, Klaus Schmierer, Tarek Yousry, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, В.М. Воронцов, Kevin J. Dawson	2008	2
16	Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study UCL Discovery (University College London) ·Ludwig Kappos, D. H. Miller, David MacManus, Ralf Gold, Eva Havrdová, Ian Czencz, Kenneth L. JoOOson, Klaus Schmierer, Tarek Yousry, Meixiao Long, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, Mdcccxxix Carolo	2006	13
17	BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis UCL Discovery (University College London) ·Ludwig Kappos, D. H. Miller, David MacManus, Ralf Gold, Eva Havrdová, Ian Czencz, CH Polman, Klaus Schmierer, A Yazdi Zadeh, Min Yang, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, Mdcccxxix Carolo	2006	11
18	Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain UCL Discovery (University College London) ·Klaus Schmierer, John William Saunby, L. Zhang, Gareth J. Barker, D. H. Miller	2004	5
19	[Medical history and politics: careers of Fritz Lejeune during the Weimar Republic and national socialism]. PubMed ·Klaus Schmierer	2002	1
20	Impaired transcallosal inhibition: an early indicator of central conduction deficits in multiple sclerosis UCL Discovery (University College London) ·Klaus Schmierer, S. Röricht, L. Niehaus, Denise Lara Oliveira Muniz	1998	1

About Klaus Schmierer

Klaus Schmierer is a scholar working on Pathology and Forensic Medicine, Neurology, Genetics, Developmental Neuroscience and Oncology, having authored 171 papers that have together received 6.9k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (107 papers), Polyomavirus and related diseases (25 papers), Peripheral Neuropathies and Disorders (21 papers), Chronic Lymphocytic Leukemia Research (21 papers), Advanced Neuroimaging Techniques and Applications (11 papers), Immunotherapy and Immune Responses (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and T-cell and B-cell Immunology (9 papers). The work is most often cited by research in Pathology and Forensic Medicine (4.3k citations), Neurology (1.8k citations), Developmental Neuroscience (331 citations), Radiology, Nuclear Medicine and Imaging (1.6k citations) and Neurology (528 citations). Klaus Schmierer has collaborated with scholars based in United Kingdom, Germany and Netherlands. Frequent co-authors include Gavin Giovannoni, David H. Miller, David Baker, Francesco Scaravilli, Daniel R. Altmann, Gareth J. Barker, Mónica Marta, Paul S. Tofts, Gareth Pryce and Benjamin Turner. Their work appears in journals such as Multiple Sclerosis and Related Disorders, Neurology, Multiple Sclerosis Journal, Journal of Neurology Neurosurgery & Psychiatry and Annals of Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact